Börse Express – ROUNDUP/Aktien New York Opening: Bad Mood

NEW YORK (dpa-AFX) – Lingering disappointment over future monetary policy continued to weigh on US stock prices on Friday. Prospects for further gains towards the end of the year are dwindling after major central banks dashed hopes interest rate hikes would soon end, analyst Craig Erlam of broker Oanda commented. Weaker-than-expected purchasing managers’ indices for US manufacturing and the services sector had no discernible impact on prices.

More recently, the leading Dow Jones Industrial index has suffered 1.04 percent to 32,856.09 points. He was then listed below 33,000 points for the first time in a good five weeks. S&P 500 at market level it fell by 1.20% to 3848.83 points. The heavily tech-heavy and recently particularly battered Nasdaq 100 it lost 0.81% to 11,252.98 points.

With the third day of losing streak looming, the second week of losing is fast approaching. Especially on Thursday, stock prices in New York fell significantly.

The initial euphoria over a stronger-than-expected drop in US inflation had already subsided on Tuesday. The US Federal Reserve, which announced a tighter-than-expected monetary policy on Wednesday, has finally announced the killjoy.

Maxar Technologies shares they managed to more than double the previous day’s value with a price jump to US$51.47. Financial investor Advent wants to buy out the manufacturer and operator of the satellite and is offering $53 a share, according to a report in the Wall Street Journal. Including the debt, the offer values ​​Maxar at $6.4 billion.

At the Adobe software company According to the figures, shareholders were happy with a 4.3% increase and a top spot on the Nasdaq 100. Earnings in the recent quarter beat expectations despite a decline. Additionally, Adobe saw sales increase by about ten percent. Several analysts have raised their price targets on the stock.

Behind it, shares of Facebook parent Meta have soared in price
by four percent after US bank JPMorgan updated him and now recommends him as “overweight.”

Conversely, vaccine maker Moderna’s newspapers paid tribute
tribute to their most recent rally: after moderate losses the previous day, it is down another five percent. On Tuesday and Wednesday, thanks to positive study results of a combination therapy of a cancer vaccine Moderna and the cancer drug pembrolizumab from Merck & Co. jumped in total to nearly a third of their value./dl/meas

 ISIN  US2605661048  US6311011026  US78378X1072

AXC0253 2022-12-16/17:21

Copyright dpa-AFX business news GmbH. All rights reserved. Redistribution, republication or permanent archiving without the prior express consent of dpa-AFX is not permitted.